Metabolic Disorders
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Lessons From Novo Nordisk’s Mads Øvlisen, The Father Of CSR
When Mads Øvlisen was persuaded by his father-in-law to join the family business, Novo Industri, in 1974 for a short stint in the legal department, little did he know it would the beginning of a lifetime of service to the company that he helped to shape into the diabetes powerhouse it is today.
Stock Watch: Swelling Obesity Sales Boost Post-Pandemic Diabetes Drug Growth
The evolution of new drugs to treat diabetes has enabled some diabetes franchises to shrug off biosimilar competition to insulins. But is some of the growth of therapies for diabetes and obesity a result of the pandemic?
Early Data On Amgen’s AMG 133 Show Potential Durability, Dosing Advantage In Obesity
The drug is dosed once every four weeks – compared with Mounjaro and Wegovy’s weekly dosing – but the company also signaled it is considering extended dosing intervals.
Two Korean Pharmas Vie For Wins In High-Need Gout Space
Based on promising Phase II data, two companies in South Korea are moving ahead with late-stage development in the gout space, with JW Pharmaceutical getting approvals to begin a multinational Phase III trial for epaminurad, while LG Chem has recently submitted an application for a Phase III program with its contender tigulixostat.
Provention Plans Two-Phase Launch Of Tzield, Pricing Drug Higher Than Expected
At nearly $194,000, the wholesale acquisition cost for Tzield came in above analysts’ $100,000-$115,000 estimates, but payer pushback is not expected as the drug faces no competition.
Amgen’s Olpasiran Maintains Competitive Profile In Lp(a) Class
The lipoprotein(a)-lowering antisense drug olpasiran reduced the cardiovascular disease risk factor Lp(a) by up to 101.1% relative to placebo. A Phase III trial will begin in December.
Novo Targets Teens With Wegovy As It Heads Off Lilly Mounjaro Threat
The Danish firm’s GLP-1 receptor agonist triggered significant weight loss in a Phase III trial in obese teenagers, sparking filing plans that could strengthen the product’s market share even as rival Eli Lilly mounts a threat with Mounjaro.
Novo’s Obesity Franchise On Track For YE22 But Diabetes Pipeline Steals Show During Q3
Updates regarding Novo Nordisk’s obesity product Wegovy dominated the Danish firm’s Q3 results call, but observers were also keen to hear of diabetes R&D milestones as Eli Lilly’s competitor Mounjaro entered the market with a bang.
Lilly Preparing For Increasing Mounjaro Demand On Top Of Solid Launch
The pharma is increasing its manufacturing capacity for tirzepatide, mindful of its potential in a second indication of obesity and the supply issues faced by competitor Novo Nordisk.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Pfizer takes on AstraZeneca and Merck & Co in prostate cancer; AstraZeneca’s gene therapy acquisition; ex-Sanofi partnering head joins AI start-up; Shionogi and Medicines Patent Pool strike deal for oral COVID antiviral; and Intercept sticks with NASH plans despite missed endpoint.
Lilly Settles On Rolling Submission For Tirzepatide In Obesity
Plan for rolling submission means US FDA filing of GIP/GLP1 agonist in obesity could be complete by April 2023, setting up possibility of late 2023 approval.
Sanofi Alliance Is Big Boost For Company Behind Type 1 Diabetes Prevention Drug
Sanofi has deprioritized its presence in type 1 diabetes in recent years but could help turn teplizumab into a game-changer blockbuster product.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.